Labcorp Holdings INC 8-K filings

Labcorp Holdings Inc. announced its third quarter 2026 financial results will be released on October 28, 2026, with a webcast to follow.

Labcorp Holdings Inc. reaffirms its 2026-2029 financial outlook while expressing concerns over potential steep annual payment cuts from new CMS clinical laboratory fee schedule rates.

Labcorp Holdings Inc. hosted its 2026 Investor Day, reaffirming full-year 2026 guidance and presenting a long-term financial outlook through 2029 with projected compound annual revenue growth of 5% to 8%.

Labcorp Holdings Inc. announced its executive management team will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026.

Labcorp Holdings Inc. announced it will host an Investor Day on September 10, 2026, where leadership will discuss strategy, capital deployment, and financial outlook.

Labcorp Holdings Inc. announced a key executive departure and internal appointment, effective September 2026, impacting leadership of its laboratory services.

Labcorp announced strong second-quarter results, exceeding expectations with significant revenue and EPS growth, leading to an upward revision of its full-year financial guidance.

Labcorp Holdings Inc. announced its Board of Directors has declared a cash dividend of $0.72 per share of common stock, payable on September 11, 2026.

Labcorp Holdings Inc. announced it will release its second quarter 2026 financial results on July 30, 2026, and will host a conference call and webcast to discuss the findings.

Labcorp announced its participation in the 2026 Jefferies Healthcare Conference, with a presentation scheduled for June 3rd.

Labcorp Holdings Inc. shareholders re-elected the board of directors, approved executive compensation, and ratified Deloitte & Touche LLP as the independent auditor for 2026.

Labcorp announced robust first-quarter 2026 results, exceeding expectations with significant revenue and EPS growth, leading to an upward revision of full-year financial guidance.

Labcorp Holdings Inc. announced its Board of Directors has declared a cash dividend of $0.72 per share of common stock, payable on June 11, 2026.

Labcorp Holdings Inc. announced it will release its first quarter 2026 financial results on April 30, 2026, followed by a conference call and webcast.

Labcorp Holdings Inc. and its subsidiary secured a $750 million senior unsecured term loan maturing in March 2028 to be used for general corporate purposes.

Labcorp announced strong fourth quarter and full year 2025 financial results, driven by growth in Diagnostics and Central Laboratory businesses, and provided optimistic 2026 guidance.

Labcorp Holdings Inc. announced the appointment of Dr. John H. Sampson, a distinguished neurosurgeon and academic leader, to its Board of Directors, effective February 9, 2026.

Labcorp Holdings Inc. has amended its receivables purchase agreement, extending the termination date and increasing its financing capacity by $125 million.

Labcorp Holdings Inc. announced it will release its fourth quarter 2025 financial results on Tuesday, February 17, 2026, followed by a conference call and webcast.

Labcorp Holdings Inc. announced its Board of Directors has declared a cash dividend of $0.72 per share payable on March 12, 2026.

Labcorp Holdings Inc. announced its participation in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference on January 13.

Labcorp Holdings Inc. announced that Mark Schroeder, Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer, will retire effective April 1, 2026.

Labcorp Holdings Inc. announced that Dr. D. Gary Gilliland will retire from its Board of Directors effective December 31, 2025, after over a decade of service.

Labcorp announced the appointment of Victor Bulto, President of Novartis U.S., to its Board of Directors, effective December 1, 2025, enhancing its focus on innovation and global healthcare leadership.

Labcorp reported strong third-quarter 2025 financial results with significant revenue and adjusted EPS growth, alongside strategic acquisitions and an upward revision to its full-year adjusted EPS and free cash flow guidance.

Labcorp Holdings Inc. announced its Board of Directors declared a cash dividend of $0.72 per share, payable December 11, 2025.

Labcorp Holdings Inc. announced it will release its third quarter 2025 financial results on October 28, 2025, followed by a conference call.

Labcorp Holdings Inc. announced its executive management team will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025.

Labcorp Holdings Inc. reported robust second-quarter 2025 financial results, exceeding revenue and earnings expectations and subsequently raising its full-year guidance for enterprise revenue, adjusted EPS, and free cash flow.

Labcorp Holdings Inc. announced its Board of Directors has declared a cash dividend of $0.72 per share, payable on September 11, 2025, to shareholders of record as of August 28, 2025.